A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance

BMJ Open

Volumn 5, Issue 5, 2015, Pages

  Watts, Sam ^a   Leydon, Geraldine ^a   Eyles, Caroline ^a   Moore, Caroline M ^b   Richardson, Alison ^c   Birch, Brian ^d   Prescott, Philip ^c   Powell, Catrin ^e   Lewith, George ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACADEMIC ACHIEVEMENT; ACTIVE SURVEILLANCE; ADULT; AGE; AGED; ANXIETY DISORDER; ARTICLE; CANCER EPIDEMIOLOGY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DEPRESSION; DIVORCE; EMPLOYMENT; ETHNICITY; HEALTH SURVEY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MARRIAGE; PREVALENCE; PROSTATE CANCER; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; UNITED KINGDOM; ANXIETY; CLINICAL TRIAL; ENGLAND; MIDDLE AGED; MULTICENTER STUDY; PROSTATIC NEOPLASMS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; QUALITY OF LIFE; SECONDARY HEALTH CARE; VERY ELDERLY; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; ANXIETY; CROSS-SECTIONAL STUDIES; DEPRESSION; ENGLAND; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSTATIC NEOPLASMS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SECONDARY CARE; SURVEYS AND QUESTIONNAIRES; WATCHFUL WAITING;

EID: 84930226032     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006674     Document Type: Article

References (25)

1. Office for National Statistics. London, UK, 2012.
2. Bray F, Lortet-Tieulent J, Ferlay J, et al. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010; 46: 3040-52.
3. Dall'Era MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012; 62: 976-83.
4. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localised prostate cancer. N Engl J Med 2012; 367: 203-13.
5. National Institute for Clinical Excellence Clinical Guideline 175. Prostate cancer: diagnosis and treatment. 2014.
6. Fawzy FL, Fawzy NW, Arndt LA, et al. Critical review of psychosocial interventions in cancer care. Arch Gen Psychiatry 1995; 52: 100-13.
7. Davidson JB, Degner LF. Empowerment of men newly diagnosed with prostate cancer. Cancer Nurs 1997; 20: 187-96.
8. Salander P, Bergenheim T, Henriksson R. The creation and protection of hope in patients with malignant brain tumours. Soc Sci Med 1996; 42: 985-96.
9. Balderson N, Towell T. The prevalence and predictors of psychological distress in men with prostate cancer who are seeking support. Br J Health Psychol 2003; 8: 125-34.
10. Burnet KL, Parker C, Dearnaley D, et al. Does active surveillance for men with localized prostate cancer carry psychological morbidity? Br J Urol Int 2007; 100:540-3.
11. van den Bergh RCN, Essink-Bot ML, Robol MJ, et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009; 1: 3867-78.
12. van den Bergh RCN, Essink-Bot ML, Robol MJ, et al. Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol 2010; 183: 1786-91.
13. Department of Health. No health without mental health: a cross-government mental health outcomes strategy for people of all ages. London, UK, 2011.
14. Patel MI, DeConcini DT, Lopez-Corona E, et al. An analysis of men with clinically localised prostate cancer who deferred definitive therapy. J Urol 2004; 171: 1520-4.
15. Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 2007; 178: 826-32.
16. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Psychiatr Scand 1983; 67: 361-70.
17. Maher EJ, Mackenzie C, Young T. The use of the Hospital Anxiety and Depression Scale (HADS) and the EORTC QLQ-C30 questionnaire to screen for treatable unmet needs in patients attending routinely for radiotherapy. Cancer Treat Revised 2006; 22: 123-32.
18. Lawrie I, Lloyd-Williams M, Taylor F. How do palliative medicine physicians assess and manage depression. Palliat Med 2004; 18: 234-8.
19. Love AW, Kisssne DW, Bloch S, et al. Diagnostic efficiency of the Hospital Anxiety and Depression Scale in women with early stage breast cancer. Aust N Z J Psychiatry 2002; 36: 246-50.
20. Love AW, Grabsch B, Clarke DM, et al. Screening for depression in women with metastatic breast cancer: a comparison of the Beck Depression Inventory Short Form and the Hospital Anxiety and Depression Scale. Aust N Z J Psychiatry 2004; 38:526-31.
21. Bellardita T, Rancati T, Alvisi MF, et al. Predictors of health related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol 2013; 64: 30-6.
22. Lofters A, Juffs HG, Pond GR, et al. 'PSA-it is': knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. J Urol 2002; 168: 2516-20.
23. Schofield PE, Butow PN, Thompson JF, et al. Psychological responses to patients receiving a diagnosis of cancer. Ann Oncol 2003; 14: 48-56.
24. Watts S, Leydon G, Brich B, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 2014; 4:e003901.
25. Cockle-Hearne J, Faithful S. Self-management for men surviving prostate cancer: a review of behavioural and psychosocial interventions to understand what strategies can work, for whom and in what circumstances. Psychooncology 2010; 19: 909-22.